Alkem Laboratories announced a 17% YoY revenue increase to ₹40,010 Mn and a 22% YoY growth in EBITDA to ₹9,208 Mn in Q2 FY26. Domestic sales grew by 12.4% to ₹27,660 Mn, while international sales increased by 29.5% to ₹11,890 Mn. Alkem’s improved gross margins and operating leverage contributed to its enhanced financial performance.
Financial Highlights for Q2 FY26
Alkem Laboratories reported strong financial results for Q2 FY26, demonstrating growth across key metrics:
- Revenue from Operations: ₹40,010 Mn (up 17.2% YoY)
- EBITDA: ₹9,208 Mn with a margin of 23.0% (up 22.3% YoY)
- PAT: ₹7,651 Mn with a margin of 19.1% (up 11.1% YoY)
Domestic and International Performance
Alkem experienced robust growth in both domestic and international markets:
- Domestic Sales: ₹27,660 Mn, a 12.4% YoY increase
- International Sales: ₹11,890 Mn, a significant 29.5% YoY increase with US sales growing 28.0% to ₹7,649 Mn.
Key Growth Drivers
Several factors contributed to Alkem’s strong Q2 FY26 performance:
- Improved gross margins and operating leverage.
- Healthy traction from new product launches.
- Strong performance in the US market, particularly from the launch of Sacubitril/Valsartan and CDMO business.
R&D and Capital Expenditures
Alkem continues to invest in research and development to drive future growth:
- R&D Expenses: ₹1,302 Mn, representing 3.3% of total revenue from operations.
Operational Updates
A number of operational milestones were achieved in Q2 FY26:
- Filed 2 ANDAs and received 1 tentative ANDA approval in the US.
- Launched 4 new products in the US market.
- As of September 30, 2025, the company has 187 filed ANDAs, with 163 approvals including tentative approvals, and 2 NDA approvals in the US.
Source: BSE
